Watch CLYM. Know when insiders buy.
One email the day a filing lands. Free.
CLYM
Climb Bio, Inc.
10.87
+0.07 +0.65%
USD · close Oct 21
A free account adds a watchlist, alerts when insiders, Congress or short sellers move on your tickers, and a morning brief. Sign up
Work order
42
WATCH · insiders 25, shorts 59
Insiders, 90 days
−$1.4M
net selling · 0 buys, 1 sell
Congress, 90 days
0 / 0
no disclosures naming it
Big money
0 / 15
none of the tracked funds disclose it
Calls on record
0
nobody we score has called it yet
MKT CAP $624.3MP/E —DIV YIELD —FCF YIELD —REV TTM —NET INCOME −$57.6MNET CASH —52W 1.64 – 17.84SEC XBRL · TTM TO Invalid Date
Financials
By quarter
| Period | Revenue | YoY | Gross margin | Operating income | Net income | YoY | EPS | Op. cash flow | Capex | Free cash flow | Filed |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Q2 2026 · Jun 30 | — | — | — | −$15.4M | −$13.5M | — | -0.18 | −$10.5M | — | — | Aug 6 |
| Q1 2026 · Mar 31 | — | — | — | −$15.2M | −$13.7M | — | -0.20 | −$14.4M | — | — | Aug 6 |
| Q4 2025 · Dec 31derived | — | — | — | −$19.3M | −$17.5M | — | -0.25 | −$15.6M | $0 | −$15.6M | Mar 5 |
| Q3 2025 · Sep 30 | — | — | — | −$14.9M | −$12.9M | — | -0.19 | −$12.1M | $109K | −$12.2M | Nov 6 |
| Q2 2025 · Jun 30 | — | — | — | −$10.7M | −$8.7M | — | -0.13 | −$11.1M | — | — | Aug 6 |
| Q1 2025 · Mar 31 | — | — | — | −$23M | −$20.8M | — | -0.31 | −$15.4M | — | — | Aug 6 |
| Q4 2024 · Dec 31derived | — | — | — | −$10.9M | −$8.4M | — | 0.04 | −$5.5M | $0 | −$5.5M | Mar 5 |
| Q3 2024 · Sep 30 | — | — | — | −$11.7M | −$8.9M | — | -0.13 | −$7.6M | $0 | −$7.6M | Nov 6 |
| Q2 2024 · Jun 30 | — | — | — | −$56.4M | −$54.9M | — | -1.81 | −$667K | — | — | Nov 6 |
| Q1 2024 · Mar 31 | — | — | — | −$3M | −$1.7M | — | -0.06 | −$1.8M | — | — | Nov 6 |
| Q4 2023 · Dec 31derived | — | — | — | −$5.1M | −$3.6M | — | -0.13 | −$947K | $0 | −$947K | Mar 25 |
| Q3 2023 · Sep 30 | — | — | — | −$5M | −$4M | — | -0.15 | $3.5M | $0 | $3.5M | Nov 12 |
By fiscal year
| Year | Revenue | Gross margin | Operating income | Net income | Net margin | EPS | Op. cash flow | Capex | Free cash flow | Buybacks | Dividends paid |
|---|---|---|---|---|---|---|---|---|---|---|---|
| FY2025 · to Dec 31 | — | — | −$67.9M | −$59.9M | — | -0.88 | −$54.4M | $186K | −$54.5M | — | — |
| FY2024 · to Dec 31 | — | — | −$82M | −$73.9M | — | -1.53 | −$15.6M | $0 | −$15.6M | — | — |
| FY2023 · to Dec 31 | — | — | −$40.3M | −$35.1M | — | -1.30 | −$20.6M | $0 | −$20.6M | — | — |
| FY2022 · to Dec 31 | — | — | −$45.1M | −$45.2M | — | -1.72 | −$37.4M | — | — | — | — |
| FY2021 · to Dec 31 | — | — | −$35.7M | −$47.5M | — | -4.24 | −$36.1M | — | — | — | — |
| FY2020 · to Dec 31 | — | — | −$20.9M | −$20.7M | — | -10.49 | −$14.1M | — | — | — | — |
Every number comes from Climb Bio, Inc.'s own XBRL-tagged filings with the SEC, not a data vendor. Quarters marked derived are the fiscal year minus the three reported quarters, the same way every data provider computes Q4. Restated figures replace originals as later filings arrive.